Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana’s Platform

(2016) Tzahi Neuman et al.   Journal of Thoracic Oncology

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

(2016) Kyle C. Strickland et al.   Oncotarget

Sex-Driven Differences in Immunological Responses: Challenges and Opportunities for the Immunotherapies of the Third Millennium

(2015) Leonardo Mirandola et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012.

(2015) Kei Muro et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice

(2015) Luís Felipe Campesato et al.   Oncotarget

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

(2014) Jason Madore et al.   Pigment Cell & Melanoma Research

Early-onset colorectal cancer: A sporadic or inherited disease?

(2014) Vittoria Stigliano   WORLD JOURNAL OF GASTROENTEROLOGY

Exomics and immunogenics

(2014) Stéphane Champiat et al.   OncoImmunology

Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management

(2013) Brian Shuch et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature

(2013) Ewa Majchrzak et al.   Radiology and Oncology

Familial risk of early and late onset cancer: nationwide prospective cohort study

(2012) E. Kharazmi et al.   BMJ-British Medical Journal

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Recent Trends in Incidence of Cutaneous Melanoma among US Caucasian Young Adults

(2008) Mark P. Purdue et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY